Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505515 | 0.76 | PDCD1 (0.53) | KDM4ETDP1GRM5NPC1RAB9A | |
| SCHEMBL27412915 | 0.64 | KDM4E (0.46) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL322756 | 0.63 | KDM4E (1.00) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL29354466 | 0.63 | KDM4E (1.00) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL789163 | 0.61 | KDM4E (0.95) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL29171375 | 0.61 | KDM4E (0.95) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL11213260 | 0.61 | KDM4E (0.95) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL870201 | 0.61 | KDM4E (0.95) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL32681187 | 0.61 | KDM4E (0.95) | KDM4ETDP1NPC1RAB9ALMNA | |
| SCHEMBL31268013 | 0.61 | KDM4E (0.75) | KDM4ETDP1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | KDM4E 2855/4885TDP1 2077/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.